Experimental cancer treatments

Global Oncolytic Virus Therapy Clinical Trials Research Immunotherapy Market Insight 2026

Retrieved on: 
Sunday, April 18, 2021

b'"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:\nGlobal Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity\nGlobal Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials\nUSA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials\nImlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight\nThe ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients.

Key Points: 
  • b'"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:\nGlobal Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity\nGlobal Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials\nUSA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials\nImlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight\nThe ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients.
  • Global oncolytic virus immunotherapy market is a novel cancer treatment platform which is engineered to deliver maximum results for the cancer patients in a controlled way.
  • In a more efficient way, the therapy at clinical levels has led to the significant advancement of the global cancer therapeutics market.
  • All these are witnessed to be inclining the market towards high growth rate and market size in the future years.\nThe current clinical market associated with global oncolytic virus immunotherapy is estimated to be the result of extensive clinical research activities that have been conducted by the researchers all across the globe.

AmunBio and NorthShore University HealthSystem to Advance Cancer Immunotherapy with Next Generation Engineered Oncolytic Viruses

Retrieved on: 
Tuesday, April 13, 2021

The development of oncolytic viral therapies, which represents a unique therapeutic paradigm within Immuno-Oncology, is gaining momentum.

Key Points: 
  • The development of oncolytic viral therapies, which represents a unique therapeutic paradigm within Immuno-Oncology, is gaining momentum.
  • This technology forms the core of AmunBio\'s proprietary, multimodal therapeutic approach utilizing direct destruction of cancer cells and immune system activation.
  • AMUN-003 can be administered both locally as well as systemically.\nPreclinical studies with AMUN-003 in breast cancer alone, compared to prior oncolytic virus constructs, demonstrated near-complete breast cancer inhibition.
  • With the novel, next-generation, proprietary technology platform approach, utilizing direct destruction of cancer cells and immune system activation, patients will be uniquely positioned to defeat cancer.

OncoMyx Presents at AACR First Data Showing Multi-Armed Myxoma Virotherapy Can Modulate Anti-Tumor Immune Response

Retrieved on: 
Saturday, April 10, 2021

The data are the first to demonstrate that OncoMyxs multi-armed myxoma virotherapy upregulates anti-tumor immune response pathways, expresses transgenes in a dose and time-dependent manner, and produces anti-tumor efficacy in a preclinical model of cancer following intravenous (IV) or intratumoral (IT) dosing.

Key Points: 
  • The data are the first to demonstrate that OncoMyxs multi-armed myxoma virotherapy upregulates anti-tumor immune response pathways, expresses transgenes in a dose and time-dependent manner, and produces anti-tumor efficacy in a preclinical model of cancer following intravenous (IV) or intratumoral (IT) dosing.
  • One of OncoMyxs myxoma virotherapies (vMYX-hIL-12/Dec), which is multi-armed with interleukin-12 (IL-12) and decorin (Dec), upregulates interferon- (IFN-), and IFN-, and IL-12 response pathways, which are associated with anti-tumor immune response.
  • OncoMyx has specifically built multi-armed myxoma viruses with immunomodulatory proteins and payloads designed to stimulate anti-tumor immunity and deliver targeted cancer therapies.
  • OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus platform to orchestrate an immune response to better treat cancer.

Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses

Retrieved on: 
Friday, April 9, 2021

To-date, the only oncolytic virus that has received regulatory approval is only approved for intra-tumoral administration, restricting its use to superficial lesions.

Key Points: 
  • To-date, the only oncolytic virus that has received regulatory approval is only approved for intra-tumoral administration, restricting its use to superficial lesions.
  • The findings that will be presented at AACR demonstrate the relevance of intravenous administration of Transgenes next generation oncolytic viruses including TG6002.
  • Based on the safety profile of TG6002, several dose levels have been added to the initial Phase I clinical protocol.
  • With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

Global Immuno-Oncology Market Report 2021: Analysis, Trends, Opportunities and Unmet Needs - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 25, 2021

The "Immuno-Oncology - Market Analysis, Trends, Opportunities and Unmet Needs - Thematic Research" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immuno-Oncology - Market Analysis, Trends, Opportunities and Unmet Needs - Thematic Research" report has been added to ResearchAndMarkets.com's offering.
  • Immuno-Oncology report provides the landscape of marketed and pipeline immuno-oncology drugs across the five major classes (bispecific antibodies, cancer vaccines, cell therapies, checkpoint modulators and oncolytic viruses), opportunities, challenges, and unmet needs.
  • Immuno-oncology (IO) describes the treatment of various cancers with the use of bispecific-antibodies, cancer vaccines, cell therapies, checkpoint modulators and oncolytic viruses.
  • These classes of IO therapies achieved sales of ~$30B in 2019, which is projected to reach ~$95B by 2026.

Global Oncolytic Virus Therapy Immunotherapy Market USD 700 Million Opportunity

Retrieved on: 
Thursday, March 25, 2021

NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:
    Global Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity
    Global Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials
    USA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials
    Imlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight
    Oncolytic virus therapy constitutes of using the clinical benefits of virus for treating different diseases and specifically cancer in the pharmaceutical industry.
  • In addition, the annual growth rate set by the oncolytic virus therapy is also estimated to align the entire therapy as a self-sufficient therapy with or without combination.
  • In the research and development base for global oncolytic virus therapy, the therapy due to its widespread applications is receiving tons of investments which is however inclining the therapy market to get emerged as a therapy with numerous blockbuster products against different types of diseases.
  • In driving the entire oncolytic virus therapy at global level, there are numerous advantages that are associated with it.

Global Oncolytic Virus Therapy Immunotherapy Market USD 700 Million Opportunity

Retrieved on: 
Thursday, March 25, 2021

NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:
    Global Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity
    Global Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials
    USA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials
    Imlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight
    Oncolytic virus therapy constitutes of using the clinical benefits of virus for treating different diseases and specifically cancer in the pharmaceutical industry.
  • In addition, the annual growth rate set by the oncolytic virus therapy is also estimated to align the entire therapy as a self-sufficient therapy with or without combination.
  • In the research and development base for global oncolytic virus therapy, the therapy due to its widespread applications is receiving tons of investments which is however inclining the therapy market to get emerged as a therapy with numerous blockbuster products against different types of diseases.
  • In driving the entire oncolytic virus therapy at global level, there are numerous advantages that are associated with it.

Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma

Retrieved on: 
Thursday, March 18, 2021

ILLUMINATE-301 is a randomized, global, multi-center, open label Phase 3 trial comparing the efficacy of 8 mg intratumoral tilsotolimod in combination with 3 mg/kg ipilimumab versus 3 mg/kg ipilimumab alone in 481 patients with anti-PD-1 refractory advanced melanoma.

Key Points: 
  • ILLUMINATE-301 is a randomized, global, multi-center, open label Phase 3 trial comparing the efficacy of 8 mg intratumoral tilsotolimod in combination with 3 mg/kg ipilimumab versus 3 mg/kg ipilimumab alone in 481 patients with anti-PD-1 refractory advanced melanoma.
  • Patients in the study were randomized and treated either with 8 mg of tilsotolimod in combination with ipilimumab or with ipilimumab alone.
  • Topline results include:
    ORR of 8.8% for the combination arm and 8.6% for ipilimumab alone.
  • Disease control rate (DCR, defined as stable disease or better) of 34.5% for the combination and 27.2% for ipilimumab alone.

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

Retrieved on: 
Wednesday, March 17, 2021

We look forward to completing dose escalation and sharing first data at target dose in the latter part of this year.

Key Points: 
  • We look forward to completing dose escalation and sharing first data at target dose in the latter part of this year.
  • Cedrik Britten, M.D., Chief Medical Officer at Immatics added: The clinical data emerging from this early phase of our ACTengine trials provides a first evidence of anti-tumor activity at dose levels presumed to be sub-therapeutic.
  • Secondary objectives include the assessment of T cell engraftment, persistence and infiltration into the tumor, and the assessment of objective tumor responses.
  • At data cut-off on February 16, 2021, 14 patients across multiple solid tumor indications, including non-small cell lung cancer, head & neck cancer, melanoma, synovial sarcoma and others, received ACTengine T cell products.

Replimune to Present at the American Association for Cancer Research Annual Meeting 2021

Retrieved on: 
Thursday, March 11, 2021

WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 10-15, 2021 and May 17-21, 2021.

Key Points: 
  • WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 10-15, 2021 and May 17-21, 2021.
  • Both full posters will be available for on-demand viewing on the AACR Annual Meeting 2021 website starting at 8:30 am ET on April 10, 2021 and will also be posted to the presentations section of the Replimune website at https://ir.replimune.com/events-and-presentations/presentations .
  • Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer.
  • The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers.